EN DE
Watch Hangzhou Biotest Biotech Co Ltd for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Hangzhou Biotest Biotech Co Ltd (688767) fair value: what the stock is really worth

As of Nov 17, 2026: fair value (intrinsic value) of Hangzhou Biotest Biotech Co Ltd stock ¥10.08, price ¥37.62, that is 73.2% below the price, quality 56 out of 100. Rating: strongly overvalued. Calculated from audited financials with 16 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare CN · ISIN CNE1000050H0

HB Hangzhou Biotest Biotech Co Ltd logo Some data Nov 13, 2026

Hangzhou Biotest Biotech Co Ltd

688767 · SHG

Far too expensive (fair value 73% below the price) and price moving sideways, but solid company: meets 1 of 3 rules.

Get notified free when this changes
Low debt 
Ranks above peers (9/12) 
Quality 56/100 
Price moving sideways (no uptrend) 
Thin margins · 4.4% net margin (TTM) 
Some data 
Costs 235 times its yearly profit. 
Changed on Oct 27: ¥6.89 → ¥10.08 
Fair value ¥10.08 · Strongly overvalued 
Weak Growth (revenue 5y −12.3 %/yr in CNY) 
Negative free cash flow 
1.9% dividend yield · Pays more than it earns
Narrow moat 27/100 · thin data
Watch Hangzhou Biotest Biotech Co Ltd for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

¥84.75 ¥15.19 Fair Value ¥10.08 Sep 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 13, 2026.

How to read this chart

60‑month range ¥15.19 – ¥84.75 · fair‑value band ¥9.83 – ¥12.43 · the ¥37.62 price screens above the ¥10.08 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 13, 2026.

Follow Hangzhou Biotest Biotech Co in your weekly email

Every Wednesday you see whether Hangzhou Biotest Biotech Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Hangzhou Biotest Biotech Co.,Ltd. engages in the research and development, manufacture, sale, and service of in vitro diagnostic assays and reagents, and instruments in China and internationally.

Show moreShow less

The company offers medical test products for fertility health, cardiology, oncology, inflammation, biochemistry, and various infectious diseases. It also provides veterinary test kits; fluorescence immunoassay rapid test kits; and other rapid testing kits.

In addition, the company is widely utilized across various medical institutions, judicial testing systems, third-party testing organizations, Centers for Disease Control and Prevention (CDC), and private clinics. The company was founded in 2008 and is based in Hangzhou, China.

Stock analysis

Hangzhou Biotest Biotech Co Ltd (688767) currently trades at ¥37.62, while our model-based Fair Value estimate is ¥10.08, 73% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the Multiples group reads highest at a median of ¥15.68 per share, and 1 of the 16 models we run sit above the ¥37.62 price.

Bear case: the Growth Earnings group reads lowest at ¥5.73, and 15 of the 16 models stay below the price. Data coverage for this calculation is medium.

Scenario range: ¥9.83 (bear) to ¥12.43 (bull), the price of ¥37.62 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Hangzhou Biotest Biotech Co Ltd reported revenue of 448M CNY in FY2025 versus 1.8B CNY in FY2021, a compound −29.5%/yr. Reported net income was 46.8M CNY in FY2025, compounding −51.3%/yr from FY2021.

Key figures

Market cap 5.5B CNY (≈ $827M) Small · P/E ratio 235.1 · P/S ratio 12.0 · EPS (TTM) ¥0.1600 · Dividend yield 1.9% · Net margin 4.4% · Return on equity 0.9% · Return on assets (EBIT) 17.4% (5-year average).

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 27 out of 100 (low confidence).

What moves the price

The share trades about 21% below its 52-week high and 25% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −73%, 688767 screens richer than that median.

Fair Value models

Bear ¥9.83 Fair Value ¥10.08 Bull ¥12.43
Price ¥37.62 · Downside -73.2%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
Residual Income ¥9.83 ¥10.08 ¥10.63 76
EPV ¥12.24 ¥12.57 ¥12.85 74
ROIC Compounder ¥12.24 ¥12.57 ¥12.85 72
All 16 models by family
Earnings-Based
Graham-Dodd ¥2.13 ¥9.10 ¥12.43 64
Lynch FV ¥3.65 ¥5.21 ¥6.77 61
PEG = 1.0 ¥3.65 ¥5.21 ¥6.77 57
EPV ¥12.24 ¥12.57 ¥12.85 74
Dividend Discount
Gordon GGM ¥8.39 ¥15.21 ¥21.06 68
DDM Multi-Stage ¥8.39 ¥13.85 ¥16.24 67
Multiples
P/E Multiple ¥5.17 ¥6.89 ¥8.62 63
P/S Multiple ¥4.00 ¥5.33 ¥6.66 58
P/B Multiple ¥47.47 ¥63.30 ¥79.12 55
EV/EBIT ¥14.92 ¥16.35 ¥17.77 66
EV/EBITDA ¥15.88 ¥17.62 ¥19.36 67
EV/Revenue ¥13.70 ¥15.01 ¥16.32 54
Asset-Based
NCAV (Graham) ¥6.59 ¥9.99 ¥12.49 54
Economic Profit
Residual Income ¥9.83 ¥10.08 ¥10.63 76
ROIC Compounder ¥12.24 ¥12.57 ¥12.85 72
Growth Earnings
Growth-Adj P/E ¥4.01 ¥5.73 ¥7.45 67

Open the full fair value analysis →

Quality Score breakdown

Overall quality 56/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 26
How much profit the company makes from its sales and capital
Quality Growth 27
Are margins and returns getting better?
Cashflow 46
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 67
Does it invest with discipline instead of growing at any price?
Low Volatility 45
How calm the share price moves, does not count
Price momentum 30
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 33
Distance to the 52-week high, does not count
New shares 89
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 8/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−19.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−38.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−12.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+17.7%
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−37.4%
Earnings growth per share plus dividend.
Earnings per share, growth per year−39.3%
Dividend (yield on the price)1.9%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.59% → 11%

688767 screens overvalued: fair value 73% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Hangzhou Biotest Biotech Co Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks

Beats the industry median on 9/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score 56 · Top 25%
Fair Value upside −73.2% · Bottom 25%
Profitability
Return on equity (12 months) 0.9% · Above median
Return on assets 1.8% · Top 25%
Net margin (12 months) 4.4% · Above median
Operating margin (12 months) 0.2% · Above median
Growth and dividend
Revenue growth (quarter YoY) 8.6% · Above median
Dividend yield (12 months) 1.9% · Above median
Balance sheet
Debt / equity 0.01× · Lowest 25%

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/E (12 months) 235.1× · Priciest 25%
P/B 2.32× · Cheaper than median
P/S (12 months) 11.98× · Pricier than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 1
FUTURE (revenue growth)43 · sector 36
PAST (return on equity)3 · sector 0
HEALTH (low debt)100 · sector 96
DIVIDEND (yield)37 · sector 20

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $952.40 $1,275 +34% vs 688767
Vertex Pharmaceuticals Incorporated VRTX $537.79 $592.46 +10% vs 688767
Samsung Biologics Co 207940 1,414,000 KRW 1,552,100 KRW +10% vs 688767
argenx SE ARGX $950.95 $908.40 −4% vs 688767
CSL Limited CSL A$199.55 A$186.49 −7% vs 688767
Moderna, Inc MRNA $215.27 $135.64 −37% vs 688767
BeOne Medicines AG 6160 HK$247.40 HK$152.92 −38% vs 688767
Revolution Medicines, Inc RVMD $166.87 $88.78 −47% vs 688767
Celltrion, Inc 068270 213,000 KRW 74,945 KRW −65% vs 688767
Royalty Pharma plc RPRX $68.53 $19.01 −72% vs 688767

Explore undervalued stocks

More undervalued Healthcare stocks →

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Hangzhou Biotest Biotech Co Ltd: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Hangzhou Biotest Biotech Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/688767

Frequently asked questions

Is Hangzhou Biotest Biotech Co Ltd (688767) overvalued or undervalued?
As of Nov 13, 2026, our model estimates a fair value of ¥10.08 versus a price of ¥37.62, about 73% lower (overvalued).
What is the fair value of 688767?
Our model-based fair value for Hangzhou Biotest Biotech Co Ltd is ¥10.08 (as of Nov 13, 2026), built from audited fundamentals. The current price: ¥37.62.
What is the quality score of 688767?
Hangzhou Biotest Biotech Co Ltd has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Hangzhou Biotest Biotech Co Ltd (688767)?
Our model-based price target is the fair value of ¥10.08 (as of Nov 13, 2026) from 16 valuation models. Cautious scenario ¥9.83, optimistic scenario ¥12.43. It is a calculation from audited fundamentals, not an analyst target.
What is the Hangzhou Biotest Biotech Co Ltd stock forecast for 2026?
Our models put fair value at ¥10.08, about 73% lower versus a price of ¥37.62 (overvalued). Cautious scenario ¥9.83, optimistic scenario ¥12.43. The calculation is refreshed regularly with new filings.
What is the revenue of Hangzhou Biotest Biotech Co Ltd (688767)?
Hangzhou Biotest Biotech Co Ltd reported trailing-twelve-month revenue of about 459M CNY (latest available figure, as of Nov 13, 2026).
Does Hangzhou Biotest Biotech Co Ltd pay a dividend?
Hangzhou Biotest Biotech Co Ltd currently shows a dividend yield of 1.86% relative to its recent price (as of Nov 13, 2026).
How much is the dividend of Hangzhou Biotest Biotech Co Ltd (688767) and when is the ex-dividend date?
Hangzhou Biotest Biotech Co Ltd pays a dividend of ¥0.7 per share a year, a dividend yield of 1.9%. The last ex-dividend date was Jun 1, 2026. A dividend has been paid every year since at least 2022. Our assessment: Pays more than it earns. The company pays out more in dividends than it earns, and free cash flow clearly does not cover the dividend either. It may need to be cut unless profits recover.
What is the intrinsic value of Hangzhou Biotest Biotech Co Ltd (688767)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Hangzhou Biotest Biotech Co Ltd it is ¥10.08 per share (as of Nov 13, 2026), against a price of ¥37.62. It is the blended result of 16 valuation models in 6 families (Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings).
Is Hangzhou Biotest Biotech Co Ltd stock overvalued or undervalued in 2026?
As of Nov 13, 2026, 688767 trades above its calculated fair value: price ¥37.62, fair value ¥10.08, a gap of about −73% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 688767?
No. The price is what the market pays today (¥37.62); the fair value is what the company's own numbers justify (¥10.08). For Hangzhou Biotest Biotech Co Ltd the two are ¥27.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Hangzhou Biotest Biotech Co Ltd worth?
The market values Hangzhou Biotest Biotech Co Ltd at about 5.5B CNY (market capitalisation, as of Nov 13, 2026). Per share that is ¥37.62; our models calculate a fair value of ¥10.08 per share.
What do the bullish and bearish scenarios say about 688767?
Our models span a range for Hangzhou Biotest Biotech Co Ltd: cautious scenario ¥9.83, base ¥10.08, optimistic ¥12.43 per share (as of Nov 13, 2026, price ¥37.62). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 688767?
Hangzhou Biotest Biotech Co Ltd trades at a price-to-earnings ratio of 235.1 (as of Nov 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ¥10.08 is built from several models across several years. Other multiples: P/B 2.3, P/S 12.0.
How solid is the balance sheet of Hangzhou Biotest Biotech Co Ltd (688767)?
Balance-sheet figures for Hangzhou Biotest Biotech Co Ltd (as of Nov 13, 2026): return on equity 0.9%, debt of 0.01 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is 688767 from its 52-week high?
Hangzhou Biotest Biotech Co Ltd trades at ¥37.62, about 21% below its 52-week high of ¥47.48 and 25% above the low of ¥30.00 (as of Nov 17, 2026). Distance from the high says nothing about value: that is what the fair value of ¥10.08 is for.
Which stocks are comparable to Hangzhou Biotest Biotech Co Ltd?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Hangzhou Biotest Biotech Co Ltd stock attractive at the current price?
The data as of Nov 13, 2026: price ¥37.62, calculated fair value ¥10.08 (−73%), Quality Score 56/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 688767 calculated?
We run Hangzhou Biotest Biotech Co Ltd through 16 models from 6 families: Earnings-Based, Dividend Discount, Multiples, Asset-Based, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ¥10.08 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.6% above its aggregate fair value. Hangzhou Biotest Biotech Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Hangzhou Biotest Biotech Co Ltd (688767)?
The closing price on Nov 17, 2026 was ¥37.62. Our model-based fair value is ¥10.08, about 73% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Hangzhou Biotest Biotech Co Ltd right now?
The price sits above even our optimistic bull case (¥12.43). The favourable scenario is already priced in. Solid but not exceptional quality (56/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Hangzhou Biotest Biotech Co Ltd

How large is the market capitalisation of Hangzhou Biotest Biotech Co Ltd (688767)?
The market capitalisation of Hangzhou Biotest Biotech Co Ltd is 5.5B CNY (≈ $827M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Hangzhou Biotest Biotech Co Ltd (688767)?
The price-to-sales ratio of Hangzhou Biotest Biotech Co Ltd is 12.0 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Hangzhou Biotest Biotech Co Ltd (688767)?
Earnings per share at Hangzhou Biotest Biotech Co Ltd are ¥0.1600 (price ÷ EPS = P/E 235.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Hangzhou Biotest Biotech Co Ltd (688767)?
The dividend yield of Hangzhou Biotest Biotech Co Ltd is 1.9%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Hangzhou Biotest Biotech Co Ltd (688767)?
The net margin of Hangzhou Biotest Biotech Co Ltd is 4.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Hangzhou Biotest Biotech Co Ltd (688767)?
The return on equity (ROE) of Hangzhou Biotest Biotech Co Ltd is 0.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Hangzhou Biotest Biotech Co Ltd (688767)?
On an EBIT basis the return on assets of Hangzhou Biotest Biotech Co Ltd is 17.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Hangzhou Biotest Biotech Co Ltd (688767)?
The operating margin of Hangzhou Biotest Biotech Co Ltd is 0.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Hangzhou Biotest Biotech Co Ltd (688767)?
Revenue at Hangzhou Biotest Biotech Co Ltd is growing 8.6% versus a year earlier (3y avg −38.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Hangzhou Biotest Biotech Co Ltd (688767)?
Earnings per share at Hangzhou Biotest Biotech Co Ltd are down 57.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Hangzhou Biotest Biotech Co Ltd (688767) generate?
The free cash flow of Hangzhou Biotest Biotech Co Ltd is −23.4M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Hangzhou Biotest Biotech Co Ltd (688767) hold?
Hangzhou Biotest Biotech Co Ltd holds more cash than debt, 1.6B CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Hangzhou Biotest Biotech Co Ltd in the live analysis

One click puts Hangzhou Biotest Biotech Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.